Cat: IPD-X17422

Recombinant Human LILRA1/LIR-6/CD85i Protein(HEK293) , His

  • Price
  • Size
  • Number

    Order now. For delivery time, please consult customer service

  • Pre-sale guidance and worry-free after-sale service
  • Quality assurance for cold chain transportation

Analytical Data

  • 基因名

    LILRA1/LIR-6/CD85i

  • 简介

    LILRA1/LIR-6/CD85i protein serves as a receptor for class I MHC antigens and plays a crucial role in immune recognition and response. Its interaction with class I MHC molecules suggests involvement in monitoring and possibly influencing immune activity. LILRA1/LIR-6/CD85i Protein, Human (HEK293, His) is the recombinant human-derived LILRA1/LIR-6/CD85i protein, expressed by HEK293 , with C-His labeled tag.

  • Application

    SPRMSTBLIITCELISA细胞实验药物筛选

  • 生物活性

    Measured by its binding ability in a functional ELISA. Immobilized Human LILRA1 at 2 μg/mL (100 μL/well) can bind Human ANGPTL7, The ED50 for this effect is 1.143 μg/mL. Measured by its binding ability in a functional ELISA. Immobilized Human LILRA1 at 2 μg/mL (100 μL/well) can bind Human ANGPTL7, The ED50 for this effect is 1.143 μg/mL.

  • 别名

    Leukocyte immunoglobulin-like receptor subfamily A member 1; CD85 antigen-like family member I

  • 种属

    Human

  • 表达系统

    HEK293

  • 标签

    C-His

  • 纯度

    Greater than 95% as determined by reducing SDS-PAGE.

  • 蛋白编号

    O75019-1

  • 表达区间

    P17-N461

  • 氨基酸序列

    PRTHVQAGTLPKPTLWAEPGSVITQGSPVTLWCQGILETQEYRLYREKKTAPWITRIPQEIVKKGQFPIPSITWEHTGRYRCFYGSHTAGWSEPSDPLELVVTGAYIKPTLSALPSPVVTSGGNVTLHCVSQVAFGSFILCKEGEDEHPQCLNSQPRTHGWSRAIFSVGPVSPSRRWSYRCYAYDSNSPHVWSLPSDLLELLVLGVSKKPSLSVQPGPIVAPGESLTLQCVSDVSYDRFVLYKEGERDFLQLPGPQPQAGLSQANFTLGPVSRSYGGQYRCSGAYNLSSEWSAPSDPLDILIAGQFRGRPFISVHPGPTVASGENVTLLCQSWGPFHTFLLTKAGAADAPLRLRSIHEYPKYQAEFPMSPVTSAHSGTYRCYGSLSSNPYLLSHPSDSLELMVSGAAETLSPPQNKSDSKAGAANTLSPSQNKTASHPQDYTVEN

  • 蛋白长度

    Extracellular Domain

  • 分子量

    70-75 kDa

  • 内毒素

    < 1.0 EU per μg protein as determined by the LAL method.

  • 性状

    Freeze-dried powder

  • 缓冲液

    PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.

  • 复溶方法

    Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.

  • 个性化定制

    点位突变 标签定制 buffer定制 全长蛋白定制

  • 稳定性测试

    The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.

  • 保存条件 & 期限

    Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

  • 运输条件

    In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.

Quality inspection process

Related Products

Protein Description

LILRA1, also known as LIR-6 or CD85i, belongs to the immunoglobulin superfamily, specifically the leukocyte immunoglobulin-like receptors (LIR) that play vital roles in immune regulation. This receptor is primarily expressed on myeloid cells and is involved in modulating immune responses, particularly in the context of inflammation and infection. It functions by inhibiting immune cell activation, thereby helping to maintain homeostasis and prevent excessive immune responses that could lead to autoimmunity or tissue damage. Research has shown that LILRA1 can bind to various ligands, including MHC class I molecules, which further highlights its importance in modulating T cell responses. Additionally, studies suggest that LILRA1 may play a role in tumor immunology, influencing the microenvironment and affecting the efficacy of anti-tumor immunity. The generation of recombinant LILRA1 protein has enabled further investigation into its structural properties, ligand interactions, and biological functions. Understanding the mechanisms by which LILRA1 regulates immune responses could provide valuable insights for therapeutic strategies aimed at enhancing immune responses in cancer or dampening inflammation in autoimmune diseases. As such, LILRA1 presents a promising target for novel immunotherapies and could lead to advancements in personalized medicine.


客服热线

027-8586 6806

E-mail

sales@ipodix.cn

人工客服①

汪经理

18007124176


加微信咨询

人工客服②

简经理

18164034885


加微信咨询
IPODIX North America (HQ)
Proteintech Group, Inc
5500 Pearl Street, Suite 400
Rosemont, IL 60018, USA
1-888-478-4522
proteintech@ptglab.com
IPODIX North America (HQ)
Proteintech Group, Inc
5500 Pearl Street, Suite 400
Rosemont, IL 60018, USA
1-888-478-4522
proteintech@ptglab.com
IPODIX North America (HQ)
Proteintech Group, Inc
5500 Pearl Street, Suite 400
Rosemont, IL 60018, USA
1-888-478-4522
proteintech@ptglab.com
  • 30000+

    Recombinant

  • 100+

    Researcher

  • 100+

    Countries Served

  • ISO

    Certified Quality

Committed to Quality
Driven by Innovation

Learn More About US